Virginia Bio+Tech Partnership Authority Board of Directors

The Virginia Biotechnology Research Partnership Authority (Activation Capital Board of Directors) is the supervisory board of the Virginia Biotechnology Research Partnership Authority (Activation Capital), a political subdivision of the Commonwealth. The Authority Board manages the assets of the organization and advises the President/CEO on how to best manage the resources and grow our life sciences and advanced technology ecosystem in Central Virginia and across the Commonwealth.

Created by the General Assembly, the Authority and its board is charged with disseminating knowledge pertaining to scientific and technological research and development and promoting economic development.

The Authority is governed by a nine-member board of directors, including:

Michael Rao, Ph.D. (Chairman): President, Virginia Commonwealth University ex officio
Ken Ampy: Co-Founder & CEO, Astyra
Eric Edwards, M.D., Ph.D.: Co- Founder and CEO, Phlow Corporation
Caren Merrick: Secretary of Commerce and Trade, Commonwealth of Virginia ex officio
The Honorable Levar Stoney: Mayor, City of Richmond ex officio
Bob Mooney: CFO, Phlow Corporation and Co-Founder/Managing Director, NRV
Vida Williams: Chief Data Officer, Singlestone Consulting
Art Espey, Managing Director, Paladin Global Services, LLC
Charles Macfarlane, Managing Member, Macfarlane Partners, LLC
Chandra Briggman, Executive Director

Authority Board Involvement

Since inception, the Virginia Biotechnology Research Partnership Authority has been involved in issuing tax exempt as well as taxable bonds for a variety of projects including:

1998 – $31 million tax exempt series to finance Biotech Two laboratories for the Commonwealth of Virginia to house the Virginia Department of Forensic Science and Office of the Chief Medical Examiner
1999 – $14 million taxable lease revenue bonds to refinance Biotech One, multi-tenant building first constructed in 1996 under a Master Lease arrangement with Virginia Commonwealth University
Series 1999A – $1.54 million Industrial Development Revenue Bonds; and Series 1999B – $1.21 million taxable Industrial Development Revenue Bonds to finance the North American Research and Development Center for Infilco Degremont
Series 2001 – $60 million lease revenue bonds to finance Biotech Six laboratories for the Commonwealth of Virginia to house the Division of Consolidated Laboratories and Virginia Department of Agriculture and Consumer Services
Series 2002 – $12 million variable rate revenue bonds to finance the United Network for Organ Sharing U.S. headquarters (Biotech Seven)
Series 2006 – $14 million variable rate revenue bonds to finance the new facilities for Virginia Blood Services in Henrico County, Virginia
Series 2013 – $20 million variable rate tax exempt bonds for ITxM to acquire Virginia Blood Services and to pay off Series 2006 Bond

Virginia Bio+Tech Partnership Authority Board of Directors

Authority Board Involvement

activationcapital

Who We Are

News & Resources

Start a Conversation